Bedford, MA (May 2016) – First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) today announced its selection by the Massachusetts Life Sciences Center (MLSC) to receive $750,000 in Accelerator loan financing as a promising early stage company.
According to the MLSC press release, “Launched in 2009, the Accelerator program offers loans of up to $750,000 per company and seeks to “de-risk” start-up companies that are in need of financing to serve as flexible working capital or for the purchase of capital assets. The program provides support to companies at a critical stage of their development cycle, enabling them to conduct vital research and proof of concept studies, and attract subsequent investment while improving the odds of bringing cutting-edge innovation to the marketplace and to patients.”
About First Light Biosciences
Based in Bedford, Massachusetts, First Light Biosciences is developing breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for the infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with affordability and ease-of-use. To learn more, visit www.firstlightibio.com